Fructose diet alters gut microbiota composition. by Sungjoon Cho (4385851)

The relationship between prey capture kinematics and tooth size in ray-finned fishes. by Nick Peoples (21593888)

Utilizing a fluorescent channel for improving the segmentation of sporulating cells. by N. Ezgi Wood (6519662)

“…<b>(C)</b> Out of 32868 cell segmentation events, 89.5% of them have a greater area when the composite image is used for segmentation. …”

Changes in the body color of cherry shrimp (<i>N</i>. <i>davidi</i> var. red) across different feed treatment groups (Control, AX100, AX100 + BP, AX200, AX200 + BP) over time. by Wei-Wei Hou (3405947)

Effect of sampling effort on estimates of ANOSIM R and PERMANOVA R² effect sizes and 95% confidence intervals. by Ryoko Oono (4691824)

Related to Fig 1. by Amy E. Schade (15368259)

Image_5_Evaluation of the Biodistribution of Mesenchymal Stem Cells in a Pre-clinical Renal Tuberculosis Model by Non-linear Magnetic Response Measurements.TIF by Natalia Yudintceva (10714824)

Additional file 5 of Organization of self-advantageous niche by neural stem/progenitor cells during development via autocrine VEGF-A under hypoxia by Taichi Kashiwagi (2430256)

“…NeuN+ neurons were significantly decreased by the hypoxic condition (Mean ± SEM, n = 4, *** p = 0.00028. …”

The efficiency of OPTN KD in mouse TA muscle by AAV shRNA. by Xiao Chen Shi (8611887)

Involvement of PPARα in DEX-mediated inhibition of BCO1 gene expression. by Xiaoming Gong (19039)

Table_1_Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies.do... by Roger H. Kobayashi (6291587)

“…Octanorm (marketed as cutaquig® in USA and Canada) is a new 16.5% solution of human SCIG, manufactured by a process based on that of the intravenous preparation (IVIG) octagam®.…”

Table_2_Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies.do... by Roger H. Kobayashi (6291587)

“…Octanorm (marketed as cutaquig® in USA and Canada) is a new 16.5% solution of human SCIG, manufactured by a process based on that of the intravenous preparation (IVIG) octagam®.…”

Table_2_Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies.do... by Roger H. Kobayashi (6291587)

“…Octanorm (marketed as cutaquig® in USA and Canada) is a new 16.5% solution of human SCIG, manufactured by a process based on that of the intravenous preparation (IVIG) octagam®.…”

Table_1_Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies.do... by Roger H. Kobayashi (6291587)

“…Octanorm (marketed as cutaquig® in USA and Canada) is a new 16.5% solution of human SCIG, manufactured by a process based on that of the intravenous preparation (IVIG) octagam®.…”

Table 1_Multi-omics-based phenotyping of AFG3L2-mutant lymphoblasts determines key factors of a pathophysiological interplay between mitochondrial vulnerability and neurodegenerati... by Menekse Oeztuerk (20756606)

“…Mutations in AFG3L2 are implicated in a spectrum of diseases, including spinocerebellar ataxia type 28 (SCA28) and spastic ataxia 5 (SPAX5), as well as other systemic conditions. …”

Image 1_Multi-omics-based phenotyping of AFG3L2-mutant lymphoblasts determines key factors of a pathophysiological interplay between mitochondrial vulnerability and neurodegenerati... by Menekse Oeztuerk (20756606)

“…Mutations in AFG3L2 are implicated in a spectrum of diseases, including spinocerebellar ataxia type 28 (SCA28) and spastic ataxia 5 (SPAX5), as well as other systemic conditions. …”

Body weight and fat mass were reduced in homozygous <i>Slc25a21^{tm1a(KOMP)Wtsi}</i> mice. by Simon Maguire (538578)

“…Fat mass is presented as a boxplot, with median, 25^th and 75^th percentile (box), and the lowest and highest data point within 1.5× inter quartile range (whiskers) shown (C,D). …”

AGAPP: efficacy of first-line cisplatin, 5-fluorouracil with afatinib in inoperable gastric and gastroesophageal junction carcinomas. A Hellenic Cooperative Oncology Group study by George Zarkavelis (10817434)

“…The ORR in the per protocol population (PP) was 42.9%. Within a median follow-up of 56 months, the median PFS and OS in the ITT population was 5.0 and 8.7 months, respectively. …”

Image_1_The prevalence of diabetes and thyroid related autoantibodies in Sri Lankan children with type 1 diabetes and their unaffected siblings – The utility of a new screening ass... by Navoda Atapattu (14570081)

“…</p>Results<p>The median age (IQR) of 235 T1D children and 252 unaffected siblings was 11 (8.4, 13.2) and 9 (5.4, 14.9) years respectively, and the duration of T1D was 23 (7, 54) months. (1) T1D children (a) 79.1% were 3-Screen positive; (b) all 3-Screen positives were individual antibody positive (GADA in 74%; IA-2A 31.1%; ZnT8A 38.7%); (c) and were younger (p=0.01 vs 3-Screen negatives); (d) multiple autoantibodies were present in 45.1%; (e) IA-2A (p=0.002) and ZnT8A (p=0.006) prevalence decreased with T1D duration. …”

DataSheet_1_The prevalence of diabetes and thyroid related autoantibodies in Sri Lankan children with type 1 diabetes and their unaffected siblings – The utility of a new screening... by Navoda Atapattu (14570081)

“…</p>Results<p>The median age (IQR) of 235 T1D children and 252 unaffected siblings was 11 (8.4, 13.2) and 9 (5.4, 14.9) years respectively, and the duration of T1D was 23 (7, 54) months. (1) T1D children (a) 79.1% were 3-Screen positive; (b) all 3-Screen positives were individual antibody positive (GADA in 74%; IA-2A 31.1%; ZnT8A 38.7%); (c) and were younger (p=0.01 vs 3-Screen negatives); (d) multiple autoantibodies were present in 45.1%; (e) IA-2A (p=0.002) and ZnT8A (p=0.006) prevalence decreased with T1D duration. …”